Sera Prognostics, also known as "The Pregnancy Company", has been a pioneer in the biotechnology and healthcare industries since its inception in 2008. This innovative proteomic and bioinformatics firm is dedicated to empowering healthcare professionals and improving the well-being of expectant mothers and infants through precision biomarker-based tests. The company's flagship product, the PreTRM® Test, provides physicians with individualized risk assessments for premature birth, enabling proactive interventions to mitigate potential complications. Notably, in the latest funding round on 28 April 2021, Sera Prognostics secured a significant $100.00M Series E investment from a consortium of prominent investors, including Vivo Capital, aMoon, Blue Ox Healthcare Partners, Parian Global Management, and Elevance Health. This substantial backing reflects the confidence of leading venture capital firms in the company's vision and potential impact on the global healthcare landscape. With a focus on addressing various pregnancy-related complications such as preeclampsia, gestational diabetes, and growth restriction, Sera Prognostics is poised to amplify its influence and continue shaping the future of prenatal care. For those interested in being part of this transformative journey, Sera Prognostics invites individuals to explore its values, culture, and career opportunities on its website.
Sera Prognostics
The Pregnancy Company
Salt Lake City, United States
72 employees
Series E
Total: $245.59M
Biotechnology, Health Care +1
General Information
Salt Lake City, United States
BounceWatch is an independent company data service, not affiliated with Sera Prognostics. To contact Sera Prognostics, visit seraprognostics.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Sera Prognostics compare?
A PDF of Sera Prognostics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Sera Prognostics soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
United States Market
Biotechnology
About Sera Prognostics
Business keywords: proteomic, bioinformatics, pregnancy care, precision biomarker-based tests, premature birth, risk assessment, healthcare delivery, preeclampsia, gestational diabetes, complications of pregnancy, women's health, precision medicine, maternal health
Funding Rounds & Investors (11)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series E | $100.00M | 5 |
|
28 Apr 2021 |
| Series D | $36.00M | 1 |
|
13 Nov 2019 |
| Series C | $40.00M | 2 |
|
10 Jan 2017 |
| Series B | $20.00M | 5 |
|
07 Jan 2015 |
| Series B | $5.00M | 4 |
|
18 Nov 2014 |
| Venture Round | $9.16M | - |
|
12 Jun 2014 |
| Venture Round | $4.50M | - |
|
14 Mar 2014 |
| Private Equity Round | $10.23M | - |
|
21 Nov 2012 |
| Series A | $19.30M | 5 |
|
15 Nov 2011 |
| Series A | $1.40M | 3 |
|
04 Jan 2011 |
Sera Prognostics Alternatives & Competitors
View All Alternatives
Improving Pregnancy Outcomes Globally
Shaping the future of pregnancy health.
Mellitus developed a simple diagnostic test for gestational diabetes-Work continues at Harvard/MassG...
FAQ About Sera Prognostics
Source: BounceWatch company record for Sera Prognostics, https://bouncewatch.com/company/sera-prognostics, updated 30 December 2024. When citing, please name BounceWatch and link this page.
